Treatment with alpelisib–fulvestrant has been found to prolong PFS among patients with PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer who had received endocrine therapy previously in the SOLAR-1 phase III clinical trial [67]. The gene discussed is PIK3CA; the disease is breast carcinoma.